Identifying accumulation of resistance-associated mutations during tuberculosis treatment

This project monitors the effects of inappropriate initial therapy for multidrug-resistant tuberculosis (MDR-TB) on the development of additional drug resistance that will jeopardize successful treatment. Inappropriate treatment is defined in terms of treatment with drugs for which there is proven resistance, as well as inadequate dosing of the drugs. The project therefore includes detailed pharmacokinetic/pharmacodynamic assessments, and whole genome sequencing.

Patients are recruited consecutively from MDR-TB treatment centers in Moldova, Belarus, and the Netherlands. Results will be directly relevant for future treatment and monitoring guidelines.